Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Earnings for Puma Biotechnology, Inc. (PBYI)
Earnings in 2023 (TTM): $22.67 M
According to Puma Biotechnology, Inc.'s latest financial reports the company's current earnings (TTM) are $22.67 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Puma Biotechnology, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $22.67 M | $21.59 M |
| 2022 | $500 K | $912 K |
| 2021 | $-28,800,000 | $-29,100,000 |
| 2020 | $-59,800,000 | $-60,000,000 |
| 2019 | $-75,600,000 | $-82,723,000 |
| 2018 | $-113,600,000 | $-113,600,000 |
| 2017 | $-292,000,000 | $-292,000,000 |
| 2016 | $-276,000,000 | $-276,000,000 |
| 2015 | $-239,300,000 | $-239,300,000 |
| 2014 | $-142,000,000 | $-142,000,000 |
| 2013 | $-54,659,000 | $-54,659,000 |
| 2012 | $-74,300,000 | $-74,300,000 |
| 2011 | $-10,232,878 | $-10,232,878 |
| 2010 | $-15,976 | $-15,976 |
| 2009 | $-16,836 | $-16,836 |
| 2008 | $-14,083 | $-14,083 |
| 2007 | $-15,093,000 | $-15,093,000 |